Veru announces safety, body composition data from presentations at ADA

Veru announced data from two late-breaker presentations at the American Diabetes Association’s 84th Scientific Sessions, which took place on June 21-24, in Orlando, Florida. Highlights from the presentation: In a pooled analysis of 1,027 older men, postmenopausal women, and older patients with advanced cancer, enobosarm was well tolerated with an adverse event profile comparable to the control patients. Notably, there was no increase in gastrointestinal side effects with enobosarm compared to placebo treatment. 3.7% of enobosarm treated subjects versus 1.4% of placebo subjects had elevated alanine transaminase ALT levels. In enobosarm treated subjects, these elevations in ALT were transient and mild with no evidence of drug induced liver injury by Hy’s Law observed. Cardiovascular adverse event rates were similar between the two groups . The incidence of deep vein thrombosis was higher in the placebo group compared to the enobosarm group…